sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations CEO Discusses Breakthroughs in Cancer Treatment on Popular Program
Onco-Innovations Limited, noted for its focus on oncology, recently had its CEO, Thomas O'Shaughnessy, featured on Conversations That Matter. In the interview, O'Shaughnessy shared insights into the company's progress in developing treatments for colorectal cancer and other tumours. The broadcast, seen in various Canadian media, underscored Onco's commitment to precision medicine and innovative cancer therapies.
Key topics included the integration of artificial intelligence via their Inka Health AI acquisition and partnerships with prominent research organizations and big-pharma like AstraZeneca Canada. These collaborations aim to advance precision medicine in cancer treatment. O'Shaughnessy emphasized Onco-Innovations' commitment to accelerating clinical trials and achieving global impact in cancer treatment.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited